SARM
Cardarine (GW501516)
SaveA PPARδ receptor agonist (not a true SARM) originally developed by GlaxoSmithKline for metabolic and cardiovascular disease. Commonly grouped with SARMs in the performance-enhancement community.
Quick verdict
Strong preclinical endurance and fat-oxidation data, but development was halted over cancer findings in rodent studies. No approved human use.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Phase I/II data showed improvements in HDL and triglycerides. Rodent studies demonstrated dramatic endurance gains. Development was discontinued after long-term rodent carcinogenicity studies showed tumor proliferation across multiple organs.
Benefits
- Preclinical evidence for enhanced fatty acid oxidation
- Improved lipid profiles in early human trials
- Dramatic endurance increases in animal models
Dosage notes
No safe human dosing established. Clinical trials used 2.5–10 mg/day.
Side effects
- Cancer risk in rodent models
- Unknown long-term human effects
Who should be cautious
Development halted due to cancer risk in animals. Not approved for human use. WADA-banned substance.
What this page cannot tell you
The relevance of rodent carcinogenicity data to human risk at lower doses is debated but unresolved.
Leaderboard scores
- Energy50
- Weight loss45
Write a review
Sign in to write a review.